Lantheus Holdings, Inc. (LNTH)
NASDAQ: LNTH · Real-Time Price · USD
53.57
+1.73 (3.34%)
Oct 8, 2025, 4:00 PM EDT - Market closed
Lantheus Holdings Revenue
Lantheus Holdings had revenue of $378.05M in the quarter ending June 30, 2025, a decrease of -4.07%. This brings the company's revenue in the last twelve months to $1.52B, up 5.75% year-over-year. In the year 2024, Lantheus Holdings had annual revenue of $1.53B with 18.32% growth.
Revenue (ttm)
$1.52B
Revenue Growth
+5.75%
P/S Ratio
2.35
Revenue / Employee
$1,881,996
Employees
808
Market Cap
3.64B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.53B | 237.48M | 18.32% |
Dec 31, 2023 | 1.30B | 361.37M | 38.65% |
Dec 31, 2022 | 935.06M | 509.85M | 119.91% |
Dec 31, 2021 | 425.21M | 85.80M | 25.28% |
Dec 31, 2020 | 339.41M | -7.93M | -2.28% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
LNTH News
- 2 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 10, 2025 in Lantheus Holdings, Inc. Lawsuit - LNTH - PRNewsWire
- 2 days ago - LNTH INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus - GlobeNewsWire
- 5 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus - PRNewsWire
- 8 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus - GlobeNewsWire
- 9 days ago - LANTHEUS HOLDINGS, INC. (NASDAQ: LNTH) DEADLINE ALERT Bernstein Liebhard LLP Reminds Lantheus Holdings, Inc. Investors of Upcoming Deadline - GlobeNewsWire
- 13 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 10, 2025 in Lantheus Lawsuit - LNTH - PRNewsWire
- 14 days ago - Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan - GlobeNewsWire
- 16 days ago - Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH - PRNewsWire